@geeknik

This is why I AI...perspective.

Claude, what percentage of people who markers for Alzheimer’s in the spinal fluid display symptoms?

"The honest answer is: most people with positive CSF biomarkers are asymptomatic at any given time, and the individual prognosis for any one person remains genuinely uncertain.

Here's what the research shows:

**The preclinical phase is long.** Amyloid deposition has been estimated to begin perhaps 10 years or more prior to any clinical signs of dementia. CSF changes appear even earlier — decreases in CSF Aβ42 levels may precede amyloid retention as detected by PET imaging, signifying perhaps the first evidence of AD pathology in cognitively normal individuals.

**Biomarker positivity ≠ imminent or certain symptoms.** The individual outcome associated with an amyloid-positive scan is still unknown: will all amyloid-positive elderly eventually develop AD and when? Further studies are needed to know how to translate group findings into individual use.

**Conversion rates are significant but not overwhelming on shorter timescales.** One longitudinal study found that among cognitively normal individuals with amyloid pathology, the rate of conversion from negative to positive within cognitively normal elderly was about 3% per year, raised to 7% in ApoE4 carriers. And when only tracking those already amyloid-positive, the rate of conversion to MCI or dementia was about 11% over observation periods of several years.

**Stage matters.** Tau positivity and neurodegeneration are considered later stages of the disease and considered necessary for cognitive decline — so someone who is amyloid-positive but tau-negative is at substantially lower near-term risk than someone positive on all markers.

**The conceptual framing is shifting.** Some researchers assert that a positive AD biomarker does not label an individual as being on the AD continuum or spectrum — instead, amyloid positivity is treated as a risk factor.

Bottom line: if you screened a population of cognitively normal elderly for CSF AD biomarkers, the majority who test positive would show no symptoms for years to decades. Whether they all eventually convert is still an open question — cognitive resilience, copathologies, and genetics all play roles that aren't fully understood.
"